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Speaking of a new pharmacological class, which
includes the monoclonal antibodies for Calcitonin
Gene Related Peptide or its receptor (CGRP (r)) and
gepants seems to be a simple thing, given the enor-
mous expectation that has arisen around them and
the enormity of data that we have seen. The numer-
ous randomized control trials (RCTs) of the four
siblings, erenumab, fremanezumab, galcanezumab,
eptinezumab, show strong evidence for their differen-
tiated use in episodic, chronic and refractory mi-
graine, as second-line drugs for now [1, 2]. Even
studies on gepants are moving, albeit with differenti-
ated speed, in the area of prevention or acute treat-
ment of migraine. We have on the horizon the
reappearance of a pharmacological class composed of
atogepant, rimegepant and ubrogepant [3] (Fig. 1).
We now have recommendations from the European
Headache Federation on the use of monoclonal anti-
bodies that will act as a guide and as a beacon in the
coming years to be regularly updated as new scientific
evidences will be available [4].
The CGRP(r) target in migraine has solid retro-
spective roots, moving its first steps in the world of
the trigeminovascular system of CGRP over 30 years
ago, when it was demonstrated that the perivascular
administration of the powerful vasoconstrictor, nor-
epinephrine, produced the spontaneous counteract
dilation response of CGRP [5, 6]. This was coined tri-
geminovascular reflex, aborted by lesions of the tri-
geminal nerve.
Subsequent work revealed that CGRP was the neur-
onal responsible messenger [7].
The journey then had several stages, and the caravan
was always enriched with new data, up to the current
stage we celebrate today, a new pharmacological target
dedicated to migraine and based on monoclonal anti-
bodies directed against either CGRP or the CGRP recep-
tor or on small molecules with antagonism activity
towards the CGRP [1, 8].
Interfering with the important release of CGRP at
the level of neurons and fibers of the Trigeminal
Ganglion (TG), activated by the still unknown natural
switch-on originating putatively in the Central
Nervous System (migraine generator), CGRP (r) Mabs
are the most recent drug barrier able to tackle mi-
graine pain onset [1, 2].
Translational medicine has then transferred this basic
science research data to the human science, setting-up
an experimental human migraine model leading to novel
vascular mechanics insights as well as neuroimaging
studies through the use of functional MRI (fMRI) blood
oxygenation level dependent (BOLD) revealing that
CGRP acts outside the Blood-Brain-Barrier (BBB) [9].
The necessity to have these drugs now available for
patients opens a new phase, stimulates new studies
and generates the expectation of real-world data. In
the meantime, we must consider that the clinical ap-
plication of these drugs directed to the CGRP, mem-
bers of the first and only pharmacological classes
created de novo for migraine treatment, acting on the
CGRP biomarker of disease [10], maintain their
long-term efficacy reverting this way the migraine dis-
ease to a quasi-silent state [11].
With these premises, we can define this CGRP new
pharmacological class as Disease-Modifying-Migraine-Drugs
(DMMDs), for the benefit of the huge number of patients
needing therapies that, if promptly used, can slow down or
freeze or revert the natural course of migraine [12].
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Only in this way will we be able to respond to an
ever more evident cultural movement that, based on
scientific data, wants to categorize migraine not as an
ineluctable family trace but as an endemic disease,
which represents one of the major public health pri-
orities worldwide [13, 14].
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Fig. 1 The overall picture on how the new era of CGRP pathway interacting molecules is given below. These drugs are designer molecules that
have been constructed as anti-migraine [1]
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